In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial-Reference-Cited by-同舟云学术

In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial

Published:2022-04 Issue:4 Volume:9 Page:e276-e288
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Marks David I,Clifton-Hadley Laura,Copland Mhairi,Hussain Jiaull,Menne Tobias F,McMillan Andrew,Moorman Anthony V,Morley Nicholas,Okasha Dina,Patel Bela,Patrick Pip,Potter Michael N,Rowntree Clare J,Kirkwood Amy A,Fielding Adele K

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

2. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993;Rowe;Blood,2005

3. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial;Sive;Br J Haematol,2012

4. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia;Tauro;J Clin Oncol,2005

5. Long-term outcomes of allogeneic hematopoietic cell transplant with fludarabine and melphalan conditioning and tacrolimus/sirolimus as graft-versus-host disease prophylaxis in patients with acute lymphoblastic leukemia;Mei;Biol Blood Marrow Transplant,2020

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia;Chinese Medical Journal;2024-07-09

2. Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia;HemaSphere;2024-06

3. Management of ALL in adults: 2024 ELN recommendations from a European expert panel;Blood;2024-05-09

4. Measurable residual disease (MRD)-testing in haematological and solid cancers;Leukemia;2024-04-18

5. Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Transplantation and Cellular Therapy;2024-01